GlassScriptPhysician profile
Crystal Seudeal
NPI 1043743206
$3,598.21
in general payments reported to CMS, 2019-2025
30 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.06 · 2021: $596 · 2022: $928 · 2023: $599 · 2024: $844 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,005.15 | 2020-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $594.99 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $563.29 | 2020-2025 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $180.30 | 2024-2025 | |
| Pfizer INC. | $176.31 | 2021-2025 | |
| Abiomed | $132.03 | 2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $111.11 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $110.29 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $100.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $58.79 | 2025 | Evkeeza |
| Medtronic, INC. | $56.54 | 2021-2024 | Linq II |
| Lantheus Medical Imaging, INC. | $54.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.26 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $42.44 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $41.11 | 2023-2024 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.31 | 2025 | Camzyos |
| Edwards Lifesciences Corporation | $30.18 | 2025 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $26.61 | 2023-2024 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $26.17 | 2021 | |
| Integra Lifesciences Corporation | $24.15 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Atricure, INC. | $23.15 | 2025 | Synergy Ablation System |
| Recor Medical INC | $21.58 | 2024 | Paradise Renal Denervation System |
| Cardiovascular Systems INC. | $20.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.32 | 2024 | |
| Bridgebio Pharma, INC. | $20.04 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $19.72 | 2023 | Arcalyst |
| Terumo Medical Corporation | $18.68 | 2023 | Tr Band |
| Scpharmaceuticals INC. | $15.66 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.72 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $13.83 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Seudeal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.